Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 27 ·No. 34 ·2009-12-01 ·Pages 5671-3

Burstein HJ, Winer EP

Abstract

暂无摘要

MeSH Terms

Antibodies, Monoclonal/therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Breast Neoplasms/chemistry,drug therapy,pathology Female Humans Lymphatic Metastasis Receptor, ErbB-2/analysis Trastuzumab

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Receptor, ErbB-2 Trastuzumab

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Burstein Harold J

Winer Eric P

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

1527-7755

DOI

10.1200/JCO.2009.24.2222

Published

2009-12-01

Epub

2009-00-02

Pages

5671-3

Language

English

Region

United States

NLM ID

8309333

Subset

Corrections

CommentOn

PMID: 19884543

CommentOn

PMID: 19884552

CommentOn

PMID: 19884553

CommentOn

PMID: 19884557

External Links

PubMed source DOI: 10.1200/JCO.2009.24.2222 View journal details

Analysis Services

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Contact

WeChat Official Account